|
Orthologous residues
|
|
caveolin‑1 (human): Y14‑p, caveolin‑1 (mouse): Y14‑p, caveolin‑1 (rat): Y14‑p, caveolin‑1 (dog): Y14‑p, caveolin‑1 (sheep): Y14‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast), 3T3-L1 (fibroblast), A431 (epithelial), COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Src (human)
|
transfection of constitutively active enzyme, pharmacological activator of upstream enzyme, genetic transfer of constitutively active upstream enzyme, transfection of wild-type enzyme, phospho-antibody, transfection of inactive enzyme, co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell growth, altered, cell motility, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Grb7 (human)
|
SH2
|
Induces
|
|
|
co-immunoprecipitation, pull-down assay
|
|
